This is a review of my work focusing on molecular diagnostic markers, as well as the staging and surgical management of gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). We prospectively studied the clinical utility of 68Ga-DOTATATE imaging in the detection of unknown primary tumors and metastatic disease in patients with suspected or known GEP-NETs, and compared it to that of the current FDA-approved imaging modalities such as 111In- pentetreotide single-photon emission computed tomography (SPECT/CT), computed tomography (CT), and/or magnetic resonance imaging (MRI). We found that 68Ga-DOTATATE PET/CT imaging was the most sensitive in the staging and detection of unknown primary GEP-NETs. These findings have opened new avenues for the diagnosis and treatment of GEP-NETs, as well as access to precision surgery, which combined with imaging and tumor genomics, represents the future in terms of the application of personalized cancer management.